BioNTech (NASDAQ:BNTX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $113.00 price target on the stock.
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline [Yahoo! Finance]
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.
BioNTech (NASDAQ:BNTX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.